Heidi Neubauer (PhD)
Dr. Neubauer was awarded a scholarship in 2012 to commence her doctoral studies in Biochemistry at the University of Adelaide, Australia. Her PhD work, based at the Centre for Cancer Biology in Adelaide, focused on examining mechanisms of cellular transformation, where she identified a novel oncogenic role for the lipid kinase, sphingosine kinase 2. During this work, she uncovered new protein interactions and mechanisms of intracellular protein translocation relevant in the pathogenesis of glioblastoma multiforme (GBM).
In 2017, Dr. Neubauer graduated and joined the laboratory of Prof. Richard Moriggl as a postdoctoral fellow at the University of Veterinary Medicine, Vienna. Her work here explores oncogenic mechanisms of the JAK-STAT core cancer pathway, particularly in mature T-cell leukemia/lymphoma and myeloproliferative neoplasms. She is interested in understanding the role of JAK-STAT hyperactivation and driver mutations in these hematopoietic cancers, and generating novel pre-clinical models and tools to develop new treatment strategies.
Dr. Neubauer is now a University Assistant at the University of Veterinary Medicine, Vienna, and she oversees her own research team within the Moriggl group in the unit of Functional Cancer Genomics.
Dr. Neubauer is a member of the European Association for Cancer Research (EACR), the International Cytokine & Interferon Society (ICIS), and the Australian Society for Biochemistry and Molecular Biology (ASBMB).
- The role of STAT5B as an oncogene and driver of hematopoietic cancers.
- Establishing novel pre-clinical mouse models and therapeutic strategies for rare and aggressive T-cell malignancies.
- Dysregulation of the JAK-STAT pathway in the pathogenesis of myeloproliferative neoplasms.
- The involvement of the DNA Damage Response pathway and oxidative stress in T-cell cancers.
Heidi Neubauer, PhD
University of Veterinary Medicine, Vienna
Level 2, Building NA07
A-1210 Vienna, Austria